Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Eukaryotic translation initiation factor 5A-1-like (EIF5AL1) is a protein coding gene product that functions as a translation factor, promoting translation elongation and termination, especially in situations where ribosomes stall at specific amino acid sequences (such as polyproline stretches). EIF5AL1 binds between the exit (E) and peptidyl (P) sites of the ribosome, acting to rescue stalled ribosomes and is important for ribosome quality control, particularly during the CAT tailing step. Additional suggested roles include involvement in actin dynamics, cell cycle progression, mRNA decay, cellular stress responses, and potentially cell wall maintenance. Disorders linked to variations in EIF5AL1 include amyotrophic lateral sclerosis (ALS) and certain hereditary motor neuronopathies. EIF5AL1 is not currently a well-established direct therapeutic target, and no known interacting drugs or associated biomarkers or notable safety concerns have been documented[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic translation initiation factor 5A-1-like (EIF5AL1).